Peptide handling
ARA-290 reconstitution calculator
Reconstitution calculator for ARA-290, prefilled for its 4 and 8 mg vials. Get the concentration, the dose volume and the U-100 syringe reading.
Start from a compound
Fills the vial size and a starting water volume. Only compounds with a citable range fill a dose.
The second is the question asked once the syringe is already filled, or when checking a vial someone else reconstituted.
1 mg = 1,000 mcg. Published figures are usually micrograms; vial labels are milligrams.
- Draw to
- 100 unitson a U-100 syringe
- Dose
- 2000 mcg
- Dose volume
- 1 mL
- Concentration
- 2 mg/mL
- Per unit
- 20 mcg
- Doses per vial
- 2whole doses; a partial one is not counted
Shown on a 100-unit (1 mL) U-100 syringe, the smallest that holds this draw.
ARA-290 — Limited human data
From human studies that are small, early-phase, or for a different indication than the one this range is usually cited for. The prefilled dose is the low end of that range, varies by study — daily subcutaneous in most trials, three times weekly intravenous in the earliest pilot.
Vial size and water volume are a starting point for the arithmetic, not a recommendation.
Adding more water makes the same dose a larger, easier-to-read mark on the syringe. It does not change how many doses the vial holds.
Vial sizes and starting volume
ARA-290 is commonly supplied in 4 mg and 8 mg vials. The calculator opens on a 4 mg vial with 2 mL of bacteriostatic water — a starting point for the arithmetic, not a recommendation. Change either and everything recalculates.
That combination gives 2 mg/mL, so one insulin unit holds 20 mcg and a 2000 mcg dose is 100 units.
What dose to enter
A range of 2000–8000 mcg per dose can be cited for ARA-290, varies by study — daily subcutaneous in most trials, three times weekly intravenous in the earliest pilot. The dose field opens at the low end of it.
Limited human data
From human studies that are small, early-phase, or for a different indication than the one this range is usually cited for.
- Targeting the innate repair receptor to treat neuropathy. — Review of named human pilot trials. Covers the sarcoidosis, diabetic neuropathy, and diabetic macular edema pilot trials the schedule above is drawn from, spanning 1-8 mg doses by IV and subcutaneous routes.
Related
- ARA-290 — the product page, with its current batch.
- Bacteriostatic water — what goes in the vial.
- Peptide reconstitution calculator — the general version, with the blend and half-life calculators alongside it.
- Dosing reference — published schedules, each with the evidence behind it.
For research use only. This tool performs arithmetic on figures you supply — it is not medical guidance and does not recommend a dose for any compound.